Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) Major Shareholder Sells $4,167,197.66 in Stock

Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) major shareholder Global Strategic Fund I. Venbio sold 399,923 shares of the business’s stock in a transaction dated Tuesday, April 19th. The stock was sold at an average price of $10.42, for a total transaction of $4,167,197.66. Following the sale, the insider now directly owns 3,273,451 shares in the company, valued at $34,109,359.42. The sale was disclosed in a legal filing with the SEC, which is available through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of CMPI remained flat at $$10.39 during trading hours on Thursday. 241,103 shares of the stock traded hands, compared to its average volume of 95,918. The company has a 50-day moving average price of $3.52 and a 200 day moving average price of $3.40. The company has a market cap of $224.75 million, a P/E ratio of -3.66 and a beta of 0.61. Checkmate Pharmaceuticals, Inc. has a 52-week low of $2.00 and a 52-week high of $10.45.

Checkmate Pharmaceuticals (NASDAQ:CMPI – Get Rating) last announced its quarterly earnings data on Tuesday, March 29th. The company reported ($0.62) earnings per share for the quarter. Analysts forecast that Checkmate Pharmaceuticals, Inc. will post -3.14 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Checkmate Pharmaceuticals stock. Millennium Management LLC bought a new stake in shares of Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 40,422 shares of the company’s stock, valued at approximately $241,000. Millennium Management LLC owned 0.19% of Checkmate Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. 75.12% of the stock is currently owned by institutional investors and hedge funds.

CMPI has been the subject of a number of recent research reports. Zacks Investment Research raised shares of Checkmate Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday. BTIG Research cut shares of Checkmate Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Wednesday.

About Checkmate Pharmaceuticals (Get Rating)

Checkmate Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma.

See Also